MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 85 filers reported holding MARINUS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,464,146 | +113.0% | 3,784,366 | +187.4% | 0.02% | +114.3% |
| Q2 2023 | $14,301,186 | +102.0% | 1,316,868 | +28.4% | 0.01% | +75.0% |
| Q1 2023 | $7,078,262 | +306.3% | 1,025,835 | +134.4% | 0.00% | +300.0% |
| Q4 2022 | $1,742,046 | -40.2% | 437,700 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $2,911,000 | +37.4% | 437,700 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $2,118,000 | -36.6% | 437,700 | +22.5% | 0.00% | 0.0% |
| Q1 2022 | $3,340,000 | -21.3% | 357,200 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $4,244,000 | +4.4% | 357,200 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $4,065,000 | -36.6% | 357,200 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $6,408,000 | +15.9% | 357,200 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $5,529,000 | +26.9% | 357,200 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $4,358,000 | – | 357,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,629,622 | $33,936,000 | 7.88% |
| VR Adviser, LLC | 3,156,803 | $29,516,000 | 4.78% |
| Bleichroeder LP | 1,322,463 | $12,365,000 | 2.19% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $13,380,000 | 1.30% |
| 683 Capital Management, LLC | 1,932,829 | $18,072,000 | 0.97% |
| Granite Point Capital Management, L.P. | 472,056 | $4,414,000 | 0.92% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,766,000 | $25,862,000 | 0.79% |
| Avoro Capital Advisors LLC | 3,150,000 | $29,453,000 | 0.54% |
| Artal Group S.A. | 1,000,000 | $9,350,000 | 0.39% |
| Stonepine Capital Management, LLC | 56,747 | $531,000 | 0.22% |